#1 Clinical Trials Search in Europe

Simoctocog Alfa

Simoctocog Alfa, marketed as Nuwiq, is a recombinant human coagulation factor VIII being studied in clinical trials for the treatment of hemophilia A. These trials aim to evaluate its safety, efficacy, and long-term outcomes in various patient populations, including those undergoing surgery and those with factor VIII inhibitors. The research explores different dosing regimens and combination therapies to improve patient care and quality of life for individuals living with hemophilia A.

Table of Contents

What is Simoctocog Alfa?

Simoctocog alfa, also known by its brand name Nuwiq, is a medication used to treat and prevent bleeding in patients with hemophilia A. Hemophilia A is a genetic disorder characterized by a deficiency in clotting factor VIII, which is essential for normal blood clotting.[1]

How Does It Work?

Simoctocog alfa is a man-made version of factor VIII. When administered to patients with hemophilia A, it replaces the missing or deficient factor VIII in their blood, helping to form stable blood clots and prevent or control bleeding episodes.[2]

Uses and Benefits

Simoctocog alfa is used for:

  • Treatment and prevention of bleeding episodes in patients with hemophilia A
  • Perioperative management (before, during, and after surgery) in patients with hemophilia A
  • Routine prophylaxis to prevent bleeding episodes in patients with severe hemophilia A

The medication has shown effectiveness in controlling bleeding and reducing the frequency of bleeding episodes in patients with hemophilia A, potentially improving their quality of life.[1][2]

Administration

Simoctocog alfa is administered through intravenous injection (into a vein). The dosage and frequency of administration depend on various factors, including the severity of the patient’s condition, the type and extent of bleeding, and the patient’s body weight. It’s typically given by a healthcare professional, but some patients may be trained to self-administer the medication at home.[3]

Clinical Studies

Several clinical trials have been conducted to evaluate the safety and efficacy of simoctocog alfa:

  • A study called NuPOWER is investigating the use of Nuwiq (simoctocog alfa) in combination with emicizumab for perioperative management in patients with severe hemophilia A undergoing major surgery.[1]
  • Another study, NuDIMENSION, is evaluating the use of Nuwiq in women and girls with hemophilia A who need factor VIII treatment for surgery.[4]
  • A long-term study is assessing the safety and efficacy of simoctocog alfa in patients with hemophilia A, including those who have developed inhibitors (antibodies) to factor VIII.[3]

These studies aim to provide more information about the effectiveness and safety of simoctocog alfa in various patient populations and clinical scenarios.

Safety and Side Effects

Like all medications, simoctocog alfa can cause side effects, although not everyone experiences them. Common side effects may include:

  • Headache
  • Fever
  • Dizziness
  • Allergic reactions (rare)

One of the most significant concerns with factor VIII replacement therapy is the development of inhibitors. Inhibitors are antibodies that the immune system produces against the replacement factor VIII, making the treatment less effective. Patients are monitored regularly for the development of inhibitors.[2][3]

Special Considerations

Some important points to consider about simoctocog alfa treatment include:

  • It’s suitable for use in both adults and children with hemophilia A.
  • The medication can be used in patients who have never been treated with factor VIII before (previously untreated patients) as well as those who have received factor VIII treatments in the past.
  • Simoctocog alfa may be used in combination with other medications, such as emicizumab, in certain clinical scenarios (e.g., during surgery).
  • Regular follow-ups with a healthcare provider are essential to monitor the treatment’s effectiveness and adjust the dosage if necessary.

If you have hemophilia A and are considering treatment with simoctocog alfa, it’s important to discuss the potential benefits and risks with your healthcare provider. They can provide personalized advice based on your specific medical history and condition.[1][4]

Aspect Details
Drug Name Simoctocog Alfa (Nuwiq)
Condition Treated Hemophilia A
Trial Populations Males aged 12+, women/girls, patients with/without inhibitors
Administration Route Intravenous injection
Key Objectives Safety, efficacy, perioperative management, ITI outcomes
Primary Endpoints Haemostatic efficacy, annualized bleeding rate, ITI success
Secondary Endpoints FVIII levels, quality of life, adverse events, treatment costs
Dosage Forms 250 IU to 4000 IU powder and solvent for solution
Trial Durations Vary from 30 days to 60 months
Combination Therapies Explored with emicizumab in some trials

FAQ

  • What is Simoctocog Alfa and how does it work? Simoctocog Alfa, also known as Nuwiq, is a man-made version of factor VIII, a protein essential for blood clotting. It works by replacing the missing or defective factor VIII in people with hemophilia A, helping their blood to clot normally and prevent or control bleeding episodes.
  • Who can participate in these clinical trials? The trials involve various groups, including male patients with severe hemophilia A (aged 12 and older), women and girls with hemophilia A, and patients with or without factor VIII inhibitors. Specific eligibility criteria vary for each study, but generally include confirmed diagnosis of hemophilia A and meeting age requirements.
  • What are the main objectives of these clinical trials? The main objectives include evaluating the safety and efficacy of Simoctocog Alfa in different scenarios, such as during major surgeries, assessing its effectiveness in preventing bleeding episodes, and studying its use in combination with other treatments like emicizumab. Some trials also aim to investigate its role in immune tolerance induction (ITI) for patients with factor VIII inhibitors.
  • How is Simoctocog Alfa administered in these trials? Simoctocog Alfa is typically administered through intravenous injection. The dosage and frequency of administration vary depending on the specific trial and the patient's condition. Some studies explore different dosing regimens, including prophylactic use and on-demand treatment for bleeding episodes.
  • What are the potential benefits and risks of participating in these trials? Potential benefits include access to a newer treatment option and close medical monitoring. Risks may include side effects such as the development of inhibitors to factor VIII, allergic reactions, or ineffective treatment. All trials monitor for adverse events and have safety measures in place to protect participants.

Ongoing Clinical Trials on Simoctocog Alfa

  • Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

    Recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Croatia Finland Germany Norway Spain +1

  • Study on the Use of Simoctocog Alfa and Emicizumab for Surgery in Patients with Severe Hemophilia A

    Recruiting

    1 1 1 1
    Investigated drugs:
    Croatia Finland France Germany Italy Spain

  • Study on the Use of Simoctocog Alfa for Women and Girls with Hemophilia A Undergoing Surgery

    Recruiting

    1 1 1 1
    Investigated drugs:
    Finland France Germany Italy Romania Spain

  • A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Denmark

Glossary

  • Hemophilia A: A genetic bleeding disorder caused by a deficiency in clotting factor VIII, leading to impaired blood clotting and increased risk of bleeding.
  • Factor VIII (FVIII): A protein in the blood that is essential for normal blood clotting. People with hemophilia A have low levels or dysfunctional factor VIII.
  • Simoctocog Alfa: A recombinant (man-made) form of human coagulation factor VIII used to treat or prevent bleeding in patients with hemophilia A.
  • Inhibitors: Antibodies that the immune system develops against factor VIII, making replacement therapy less effective or ineffective.
  • Immune Tolerance Induction (ITI): A treatment approach aimed at eliminating inhibitors in hemophilia patients by exposing the immune system to regular, high doses of factor VIII.
  • Prophylaxis: Regular treatment with clotting factor concentrates to prevent bleeding episodes in people with hemophilia.
  • Annualized Bleeding Rate (ABR): A measure used to assess the effectiveness of hemophilia treatments by calculating the number of bleeding episodes a patient experiences over a year.
  • Bethesda Units (BU): A measurement used to quantify the level of inhibitors in a person's blood. Higher BU indicates a stronger inhibitor presence.
  • Emicizumab: A bispecific antibody used for prophylaxis in hemophilia A patients, which mimics the function of factor VIII.
  • Recombinant: Referring to proteins or other substances that are produced using genetic engineering techniques, rather than derived from human or animal sources.

References

  1. http://clinicaltrials.eu/trial/study-on-the-use-of-simoctocog-alfa-and-emicizumab-for-surgery-in-patients-with-severe-hemophilia-a/
  2. http://clinicaltrials.eu/trial/57036/
  3. http://clinicaltrials.eu/trial/study-on-the-use-of-simoctocog-alfa-for-women-and-girls-with-hemophilia-a-undergoing-surgery/
  4. http://clinicaltrials.eu/trial/study-on-emicizumab-and-drug-combination-for-patients-with-haemophilia-a-and-fviii-inhibitors/